Anti-Obesity Drugs Market by Segments (Contrave, Xenical, Belviq, etc.), 2016 – 2022
Global anti-obesity drugs market segmented by approved drugs: buproprion and naltrexone (Contrave), orlistat (Xenical), lorcaserin (Belviq), phentermine and topiramate (Qsymia), and liraglutide (Saxenda).
Global anti-obesity drugs market segmented by approved drugs: buproprion and naltrexone (Contrave), orlistat (Xenical), lorcaserin (Belviq), phentermine and topiramate (Qsymia), and liraglutide (Saxenda).
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
P e r s i s t e n c e M a r k e t R e s e a r c h<br />
and Norgine Pharmaceuticals Ltd. Additionally, some other company includes Orexigen Therapeutics, Pfizer, Inc.,<br />
Takeda Pharmaceutical, Rhythm Pharmaceuticals, Shionogi USA, Vivus, Inc., and Zafgen.<br />
For information regarding permissions, contact:<br />
Persistence <strong>Market</strong> Research<br />
90 Sate Street, Suite 700 Albany, NY 12207<br />
Tel: +1-518-618-1030<br />
Email: sales@persistencemarketresearch.com<br />
Website: http://www.persistencemarketresearch.com/<br />
media@persistencemarketresearch.com<br />
<strong>Anti</strong>-<strong>Obesity</strong> <strong>Drugs</strong> <strong>Market</strong>, <strong>2016</strong> - <strong>2022</strong> Page |
Change language